Pyridoxamine (BioStratum).
BioStratum is developing pyridoxamine (Pyridorin), an advanced glycation end-product (AGE) inhibitor, for the potential prevention of diabetic nephropathy. By January 2004, phase II trials had been completed.
Giannoukakis
Nick
N
University of Pittsburgh School of Medicine, Diabetes Institute, 3460 Fifth Avenue, Pittsburgh, PA 15213, USA. ngiann1@pitt.edu
D000818:Animals; D002986:Clinical Trials as Topic; D003928:Diabetic Nephropathies / Q000188:drug therapy / Q000517:prevention & control; D017127:Glycation End Products, Advanced / Q000037:antagonists & inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D011733:Pyridoxamine / Q000138:chemical synthesis / Q000494:pharmacology* / Q000627:therapeutic use*
D017127:Glycation End Products, Advanced; D011733:Pyridoxamine